DAFNA Capital Management’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.7M | Sell |
171,998
-45,499
| -21% | -$3.27M | 2.79% | 10 |
|
|
2026
Q1 | $14.3M | Sell |
217,497
-153,500
| -41% | -$9.76M | 3.26% | 8 |
|
|
2025
Q4 | $23.6M | Sell |
370,997
-23,943
| -6% | -$1.49M | 5.48% | 5 |
|
|
2025
Q3 | $21.7M | Sell |
394,940
-3,160
| -0.8% | -$130K | 5.36% | 4 |
|
|
2025
Q2 | $13.2M | Hold |
398,100
| – | – | 3.63% | 7 |
|
|
2025
Q1 | $16M | Hold |
398,100
| – | – | 4.54% | 6 |
|
|
2024
Q4 | $18.7M | Hold |
398,100
| – | – | 4.76% | 6 |
|
|
2024
Q3 | $21M | Hold |
398,100
| – | – | 4.97% | 4 |
|
|
2024
Q2 | $21.6M | Hold |
398,100
| – | – | 5.15% | 4 |
|
|
2024
Q1 | $27.9M | Sell |
398,100
-1,900
| -0.5% | -$147K | 6.35% | 3 |
|
|
2023
Q4 | $33.4M | Sell |
400,000
-79,538
| -17% | -$2.88M | 8% | 2 |
|
|
2023
Q3 | $14.1M | Buy |
479,538
+146,804
| +44% | +$4.89M | 4.39% | 3 |
|
|
2023
Q2 | $10.9M | Buy |
332,734
+56,239
| +20% | +$2.08M | 2.97% | 10 |
|
|
2023
Q1 | $9.73M | Buy |
276,495
+92,500
| +50% | +$3.77M | 2.92% | 10 |
|
|
2022
Q4 | $8.43M | Hold |
183,995
| – | – | 2.37% | 13 |
|
|
2022
Q3 | $8.91M | Sell |
183,995
-27,500
| -13% | -$1.32M | 2.4% | 11 |
|
|
2022
Q2 | $8.31M | Hold |
211,495
| – | – | 2.26% | 10 |
|
|
2022
Q1 | $7.79M | Buy |
211,495
+77,401
| +58% | +$2.75M | 2.03% | 12 |
|
|
2021
Q4 | $6.11M | Sell |
134,094
-40,906
| -23% | -$1.58M | 1.54% | 18 |
|
|
2021
Q3 | $6.25M | Buy |
+175,000
| New | +$5.15M | 1.66% | 16 |
|
|
2020
Q1 | – | Sell |
-418,727
| Closed | -$4.44M | – | 81 |
|
|
2019
Q4 | $4.44M | Hold |
418,727
| – | – | 1.53% | 18 |
|
|
2019
Q3 | $4.76M | Sell |
418,727
-58,469
| -12% | -$734K | 1.79% | 15 |
|
|
2019
Q2 | $5.37M | Buy |
477,196
+76,902
| +19% | +$742K | 2.02% | 16 |
|
|
2019
Q1 | $3.24M | Buy |
400,294
+214,468
| +115% | +$1.58M | 1.4% | 25 |
|
|
2018
Q4 | $1.17M | Buy |
185,826
+123,136
| +196% | +$903K | 0.58% | 45 |
|
|
2018
Q3 | $617K | Sell |
62,690
-6,747
| -10% | -$54.1K | 0.25% | 58 |
|
|
2018
Q2 | $576K | Buy |
+69,437
| New | +$578K | 0.27% | 60 |
|
|
2017
Q1 | – | Sell |
-210,306
| Closed | -$2.56M | – | 74 |
|
|
2016
Q4 | $2.56M | Buy |
210,306
+28,569
| +16% | +$303K | 2.24% | 14 |
|
|
2016
Q3 | $1.67M | Buy |
181,737
+31,737
| +21% | +$331K | 1.16% | 28 |
|
|
2016
Q2 | $1.42M | Buy |
150,000
+94,400
| +170% | +$775K | 1.13% | 29 |
|
|
2016
Q1 | $392K | Buy |
55,600
+15,600
| +39% | +$114K | 0.34% | 71 |
|
|
2015
Q4 | $418K | Buy |
+40,000
| New | +$392K | 0.37% | 60 |
|
Other funds holding CYTK
ACA
DAFNA Capital Management's CYTK Position: Q2 2026 in Review
DAFNA Capital Management reduced its Cytokinetics (CYTK) stake by 21% in Q2 2026, selling an estimated $3.27M and leaving 171,998 shares worth $14.7M. The position accounts for 2.79% of the portfolio, ranked #10.
DAFNA Capital Management first reported a position in CYTK in Q4 2015 and has held it in 32 quarters since. The position peaked at $33.4M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- DAFNA Capital Management held 171,998 shares of Cytokinetics worth $14.7M as of Q2 2026.
- DAFNA Capital Management sold 45,499 Cytokinetics shares in Q2 2026, an estimated $3.27M.
- Cytokinetics made up 2.79% of DAFNA Capital Management's portfolio in Q2 2026, its #10 holding.
- DAFNA Capital Management first reported a position in Cytokinetics in Q4 2015 and has held it in 32 quarters since.
- DAFNA Capital Management's Cytokinetics position peaked at $33.4M in Q4 2023.
- 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.